Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07335614 · ClinicalTrials.gov registry record · NA

Evaluation of Protein Loading on Measurement of Renal Reserve

A NA study, sponsored by MediBeacon.

Not yet
Registry status
NA
Development phase
25
Enrollment target

NCT07335614: Clinical Trial NA study, sponsored by MediBeacon.

NCT07335614 is a NA study that has not yet begun recruiting, run by MediBeacon. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07335614, a NA study, has not yet begun recruiting, sponsored by MediBeacon.

NOT YET RECRUITING
Registry status
NA
Development phase
25 participants
Enrollment target

Study Summary

The goal of this clinical trial is to evaluate the effect of protein loading on the measurement of renal reserve using the MediBeacon Transdermal glomerular filtration rate (tGFR) system. Adults with estimated glomerular filtration rate (eGFR) \>30 ml/min/1.73 m\^2 will be recruited to join the study. This is a potential new use for the tGFR for the assessment of renal reserve. Renal reserve is the increase in GFR that occurs in response to various stimuli, such as when one kidney is removed. The remaining kidney will often show an increase in GFR to compensate. Renal reserve is typically measured after a high protein meal and requires a reproducible stimulus and a repeated measurement of GFR. The main questions it aims to answer are: * To characterize the effect of protein loading on GFR (dose response curve) as assessed by the MediBeacon Transdermal GFR System * To determine Renal Reserve in participants with chronic kidney disease (CKD) using the MediBeacon Transdermal GFR System * To demonstrate whether any change in GFR following the protein stimulus is associated with a change in cardiac output using non-invasive bioimpedance (NICaS) Participants will participate in a Screening visit that will take place within 28 days of the scheduled administration of Lumitrace. On dosing day, participants will have the tGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon Transdermal GFR System initiated to collect background fluorescence. Following an injection of Lumitrace and the initiation of GFR assessments, participants will ingest a high protein meal over 15-20 minutes. They will be followed at the study center for up to 6-8 hours following administration of Lumitrace. All participants will participate in a follow-up phone call approximately 7 days after the last exposure to Lumitrace. Researchers will analyze the results to see if there is a detectable difference in fluorescence clearance rate following the high protein meal

Primary Outcome

Renal reserve (%) will be calculated as Peak glomerular filtration rate (GFR) during the assessment period minus the average baseline GFR/average baseline GFR.

Interventions

  • DEVICE MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
  • DEVICE Lumitrace

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2026-05
Est. Completion 2027-01
Phase NA
MediBeacon

11 total trials

What is known before NCT07335614 opens enrollment

NCT07335614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) is the first listed.

NCT07335614 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07335614 about?

NCT07335614 is a clinical study titled "Evaluation of Protein Loading on Measurement of Renal Reserve". The goal of this clinical trial is to evaluate the effect of protein loading on the measurement of renal reserve using the MediBeacon Transdermal glomerular filtration rate (tGFR) system. Adults with estimated glomerular filtration rate (eGFR) \>30 ml/min/1.73 m\^2 will be recruited to join the stud...

What is the current status of trial NCT07335614?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2026-05. Estimated completion is 2027-01.

What interventions are being tested in trial NCT07335614?

The interventions under investigation include: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) (DEVICE), Lumitrace (DEVICE).

Who is sponsoring clinical trial NCT07335614?

This trial is sponsored by MediBeacon, which has 11 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07335614's enrollment target sits among peer trials

25 1712th of 2000 higher than 265 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07335614, the US trial registry maintained by the National Library of Medicine. NCT07335614 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.